학술논문

First-in-human phase i study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-vegf-a antibody, in adult patients with advanced solid tumors
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 April 2018, 24(7):1536-1545)
Subject
Language
English
ISSN
15573265
10780432